Schering-Plough Afrin, Lotrimin GMP Shortcomings Cited In FDA-483 Report
This article was originally published in The Tan Sheet
Executive Summary
Batch validations at a Schering-Plough manufacturing site in Puerto Rico uncovered several problems related to Afrin nasal spray and Lotrimin antifungal, FDA-483 inspection reports show.
You may also be interested in...
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth